Epidemiology Intelligence

Uncover comprehensive Ulcerative Colitis (UC) insights in global markets

Clarivate Epidemiology Intelligence provides robust, data-driven insights into Ulcerative Colitis across global markets, covering mature, emerging, and 126 additional markets via our Extrapolated Worldwide Coverage dashboard.

Our intelligence empowers biopharma teams to:

  • UC prevalence data: Global insights across 171 countries from 40+ expert epidemiologists.
  • Market sizing & segmentation: Identify growth by disease stage, severity, and treatment status.
  • Precision forecasting: Forecast product outcomes by patient subtype and comorbidity.
  • Clinical trial optimization: Pinpoint eligible populations and ideal trial sites.
Request more information north_east

Request more information

What is Epidemiology Intelligence?

Epidemiology Intelligence is your single source of patient population intelligence, featuring a unique combination of incidence and prevalence literature review, in-depth disease-specific forecasts, and U.S. claims-based insights.

Download case studydownload

Five intuitive use cases

Benchmark market forecasts

Validate UC forecasts with global prevalence, patient flow, and treatment rate data.

Validate investments and identify growth opportunities

Assess UC market potential by analyzing population trends and disease severity segmentation.

Position your product for success

Align your UC launch strategies with real-world demographics, comorbidities, and treatment dynamics.

Inform your R&D strategy

Guide UC development with comorbidity insights and real-world patient data across key markets.

Assess clinical trial feasibility

Evaluate UC patient availability and site location potential to support trial planning and completion success.

Critical questions explored to inform your strategy

  • What is the current and projected prevalence of UC in specific countries and regions?
  • How do demographic factors influence the burden of UC?
  • What are the treatment patterns and unmet needs within the UC patient population?
  • How can understanding UC epidemiology inform strategic decisions in R&D, commercialization, and market access?

Request more informationnorth_east

10 or 20-year forecasts across 171 countries

Access disease-specific epidemiology with detailed analysis and annualized forecasts to support strategic planning and market assessment.

U.S. claims-based RWD

Gain patient segmentation based on age, gender, ethnicity and location granularity at both the national and state levels with insights from Clarivate U.S. Real-World Data.

Expert-driven disease modeling

Epidemiology forecasts are built by disease specialists using validated methods for confident, data-backed planning.

In-depth epidemiology coverage

Leverage prevalence data to support UC market assessment—developed by a team of 40+ expert epidemiologists.

Did you know that you can optimize your long-term UC strategy with our Disease Landscape & Forecast insights report?

Request more information north_east

What’s included in the reports?

  • Forecasts through 2033: Patient-based 10-year market outlooks by indication.
  • Indication-specific strategy insights: Explore treatment trends, access and reimbursement, unmet needs, and many more.
  • Late-phase pipeline intelligence:Track Phase IIb/III assets and timelines to stay ahead of competitors.
  • Expert commentary:Interpret data with clarity from our disease analysts, therapy area experts, and epidemiologists.

Request more information